Companies · Biotechnology

SeQure Dx Inc.

WALTHAM · Biotechnology

Diligence memoA one-page analyst read on SeQure Dx Inc. — recommendation, valuation, rhythm, risks.
$22.3M
Total raised · real
3
Rounds
0.8×
Latest step-up
Top 32%
Sector rank · raised
Series B
Latest stage · inferred · Tue Nov 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

SeQure Dx Inc. looks under-valued against its niche peers and is at-risk on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.12× the median modeled value of Series B Biotechnology companies in 2022–2024 (197 peers) — value vs value, same stage and era.
At-risk
  • Last raise 2.6 yr ago; this sector typically re-raises about every 14 months.
  • Past due for a raise versus sector cadence — watch for distress or a bridge.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

SeQure Dx Inc. is one of 4291 Biotechnology companies tracked from WALTHAM. By capital raised it ranks mid-pack (ahead of 69% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
7
Investors (latest)
2020
Year incorporated
2023-11-21
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$250M$500M$750M$1.0BSeries B · 2021-03-24 Raised $18M (real) Modeled valuation $508M (est)$18M$508MSeries B2021Series B · 2023-06-22 Raised $2.6M (real) Modeled valuation $29M (est)$2.6M$29MSeries B2023Series B · 2023-11-21 Raised $2.2M (real) Modeled valuation $20M (est)$2.2M$20MSeries B2023+$2.6M+$2.2MCumulative $22M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series B$17.5M · 2021
Series B extension$2.6M · 2023
Series B extension$2.2M · 2023

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed, Series A — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 25%.

Modeled valuation trajectory
$20.2M
Base estimate est.
$4.4M
Conservative case
$40.6M
Upside case
$12.1M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ba $15M–$40M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Series B · modeled $507.8M · 2021-03-242021Series B · modeled $28.9M · 2023-06-22Series B · modeled $20.2M · 2023-11-212023
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
54%
Survival probability
36% low · 66% high
1.54×/yr
Annual markup
1.86×/yr upside case
2.6 yr
Elapsed time used
2.6 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
16 mo
Avg between rounds
$8.4M/yr
Capital velocity
5.3 yr
On record since
2021
First round
3
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 3.1× above median
This company$22.3M
Sector median$7.2M
Latest round — vs other Series B rounds in sector (real $, this stage) 0.1× of median
This company$2.2M
Sector median$17.5M
Modeled value — vs sector median (estimate, all stages) 0.3× of median
This company$20.2M
Sector median$64.2M

Raised more than 69% of sector peers (real $). Modeled value above 29% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #184 of 197.

This companyCohort peer
$10.0M$100.0M$1.0B$10.0M$100.0M$1.0BCapital raised (log)Mt McKinley Medical Holding Corp USA · Series B Raised $40.0M · modeled $737.5M (est)YAP Therapeutics Inc · Series B Raised $30.1M · modeled $617.6M (est)Pinteon Therapeutics, Inc. · Series B Raised $39.2M · modeled $603.1M (est)OncXerna Therapeutics, Ltd. · Series B Raised $30.0M · modeled $590.7M (est)EpiBiologics, Inc. · Series B Raised $30.0M · modeled $569.5M (est)GIOGI Ltd · Series B Raised $27.3M · modeled $553.9M (est)SonoThera, Inc. · Series B Raised $30.4M · modeled $550.2M (est)Perceive Biotherapeutics, Inc. · Series B Raised $40.0M · modeled $544.0M (est)GIOHEALTH Ltd · Series B Raised $24.5M · modeled $498.0M (est)GIOCAN Ltd · Series B Raised $24.5M · modeled $498.0M (est)GIODIA Ltd · Series B Raised $24.5M · modeled $498.0M (est)Cerapedics Inc · Series B Raised $99.1M · modeled $491.7M (est)SeQure Dx Inc. (this company) Raised $22.3M · modeled $20.2M (est)SeQure Dx Inc.
CompanyStageRaised · realValue · estvs peer med.
Mt McKinley Medical Holding Corp USASeries B$40.0M$737.5M4.41×
YAP Therapeutics IncSeries B$30.1M$617.6M3.69×
Pinteon Therapeutics, Inc.Series B$39.2M$603.1M3.60×
OncXerna Therapeutics, Ltd.Series B$30.0M$590.7M3.53×
EpiBiologics, Inc.Series B$30.0M$569.5M3.40×
GIOGI LtdSeries B$27.3M$553.9M3.31×
SonoThera, Inc.Series B$30.4M$550.2M3.29×
Perceive Biotherapeutics, Inc.Series B$40.0M$544.0M3.25×
GIOHEALTH LtdSeries B$24.5M$498.0M2.97×
GIOCAN LtdSeries B$24.5M$498.0M2.97×
GIODIA LtdSeries B$24.5M$498.0M2.97×
Cerapedics IncSeries B$99.1M$491.7M2.94×
SeQure Dx Inc. this companySeries B$22.3M$20.2M0.12×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series B$17.5M2021-03-24$97.2M$507.8M90%
Series B$2.6M2023-06-22$14.5M$28.9M90%
Series B$2.2M2023-11-21$12.1M$20.2M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series B$17.5M2021-03-24
    • First recorded raise — entered as Series B.
    • 9 investors on this round.
  2. Series B$2.6M2023-06-22
    • Raised again after 27 mo — slower than the ~14 mo sector norm.
    • Round 6.7× smaller than the prior — bridge or down round.
    • 7 investors on this round.
  3. Series B$2.2M2023-11-21
    • Came back fast: 5 mo vs the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 7 investors on this round.
Intelligence
2025 ~Q1
Modeled next raise · ~16mo cadence
$2.2M
Modeled next size est.range $2.2M$3.5M
0.8×
Last step-up
$8.4M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Ellen E. Sheets1 other2021-03
Ellen Sheets1 other2023-06
Carl M. Berke2021-03
Isaac M. Zike2023-11
Nancy M. Hong2021-03
Sanjay Pothen2023-11
Registry & provenance

SeQure Dx Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1854843
SEC CIK
2020
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Predictive Biosciences, IncBiotechnologySeries B$26.8M$1.0Bnetwork1 shared operator · same sector · same stage
Aerovance IncBiotechnologySeries B$22.5M$19.8Msame sector · same stage
PrimeGen Biotech LLCBiotechnologySeries B$22.5M$15.9Msame sector · same stage
Gen1E Lifesciences Inc.BiotechnologySeries B$22.5M$22.5Msame sector · same stage
Xenter, Inc.BiotechnologySeries B$23.5M$15.5Msame sector · same stage
Normoxys, Inc.BiotechnologySeries B$25.3M$23.8Msame sector · same stage
Revelar Biotherapeutics, Inc.BiotechnologySeries B$18.5M$20.0Msame sector · same stage
Neutrolis Inc.BiotechnologySeries B$27.6M$16.5Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Aequus Pharmaceuticals Inc.BiotechnologySeed$20.5M88%
Enquyst Technologies Inc.BiotechnologySeries A$20.1M88%
Resilient Biotics, Inc.BiotechnologySeries A$50.1M86%
BioRegenx Inc.BiotechnologyPre-Seed$2.1M86%
SeqOnce BioSciences, Inc.BiotechnologySeed$3.6M86%
Bien-Etre Labs LLCBiotechnologyPre-Seed$38.6M85%
Biorez, Inc.BiotechnologySeries A$89.0M85%
Semba Biosciences IncBiotechnologySeed$133.2M85%
Frequently asked
How much funding has SeQure Dx Inc. raised?
SeQure Dx Inc. has raised approximately $22.3M in disclosed capital across 3 recorded financing rounds, aggregated from public filings.
What is SeQure Dx Inc.'s estimated valuation?
Provath's modeled valuation for SeQure Dx Inc. is approximately $20.2M (modeled range $4.4M–$40.6M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is SeQure Dx Inc. at?
SeQure Dx Inc.'s latest modeled financing stage is Series B. Its most recent recorded round closed around Tue Nov 21.
What does SeQure Dx Inc. do and where is it based?
SeQure Dx Inc. operates in the Biotechnology sector, based in WALTHAM.
Explore related

See where SeQure Dx Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at SeQure Dx Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.